Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Thoracic 1Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Lymphoma 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Lymphoma, Non-Hodgkin 105Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84Lymphoma, Follicular 68Hodgkin Disease 54Burkitt Lymphoma 52Multiple Myeloma 51Lymphoma, B-Cell 51Recurrence 46Lymphoma, Mantle-Cell 46Leukemia, Myeloid, Acute 44Leukemia 37Neoplasms 35Hematologic Neoplasms 32Myelodysplastic Syndromes 29Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, T-Cell 18Lymphoma, T-Cell, Peripheral 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia, B-Cell 16Lymphoma, Large-Cell, Anaplastic 15Sarcoma 13Leukemia, Biphenotypic, Acute 13Mycosis Fungoides 11Melanoma 10Lymphoma, T-Cell, Cutaneous 10

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Lymphoid × 30 days × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡